Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports

Eli Lilly told the FT it wants the UK to regularly raise NHS drug prices and phase out a multi‑billion‑pound rebate scheme if it is to resume investment, according to international businesses president Patrik Jonsson. If implemented, the proposal could materially improve Lilly's UK revenue prospects and attract pharma investment back to the UK, while increasing cost pressure on NHS budgets and raising political/regulatory risk for UK healthcare policy.

Analysis

Eli Lilly told the FT it wants the UK to regularly raise NHS drug prices and phase out a multi‑billion‑pound rebate scheme if it is to resume investment, according to international businesses president Patrik Jonsson. If implemented, the proposal could materially improve Lilly's UK revenue prospects and attract pharma investment back to the UK, while increasing cost pressure on NHS budgets and raising political/regulatory risk for UK healthcare policy.